Molecular platforms for targeted drug delivery

Maso, Katia; Grigoletto, Antonella; Vicent, Marı́a J.; Pasut, Gianfranco

doi:10.1016/bs.ircmb.2019.03.001

Cited by 26 publications

(11 citation statements)

References 229 publications

(212 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody/polymer–drug conjugates are already the fastest growing class of therapeutics within oncology . Since many aspects of these topics have been examined in previous reviews, − we will discuss only the latest trends in the bioconjugation approaches for these therapeutic conjugates: their current status, emerging technologies, and future challenges that need to be addressed for their successful clinical use.…”

Section: Introductionmentioning

confidence: 99%

Trends in Therapeutic Conjugates: Bench to Clinic

Rudra

Shakur

et al. 2020

Bioconjugate Chem.

View full text Add to dashboard Cite

In recent years, therapeutic conjugates have attracted considerable attention as a new class of drug due to their unique pharmacological properties, especially from the pharmaceutical community. Their molecular structure tunability, improved targeting specificity, and therapeutic efficacy have been demonstrated in a wide range of research and clinical applications. In this topical review, we summarize selected recent advances in bioconjugation strategies for the development of therapeutic conjugates, their emerging application in clinical settings, as well as perspectives on the direction of future research.

show abstract

Section: Introductionmentioning

confidence: 99%

Trends in Therapeutic Conjugates: Bench to Clinic

Rudra

Shakur

et al. 2020

Bioconjugate Chem.

View full text Add to dashboard Cite

show abstract

Section: Evolution Of Drug Delivery Systemsmentioning

confidence: 99%

Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies

et al. 2021

View full text Add to dashboard Cite

Doxorubicin, a member of the anthracycline family, is a common anticancer agent often used as a first line treatment for the wide spectrum of cancers. Doxorubicin-based chemotherapy, although effective, is associated with serious side effects, such as irreversible cardiotoxicity or nephrotoxicity. Those often life-threatening adverse risks, responsible for the elongation of the patients’ recuperation period and increasing medical expenses, have prompted the need for creating novel and safer drug delivery systems. Among many proposed concepts, polymeric nanocarriers are shown to be a promising approach, allowing for controlled and selective drug delivery, simultaneously enhancing its activity towards cancerous cells and reducing toxic effects on healthy tissues. This article is a chronological examination of the history of the work progress on polymeric nanostructures, designed as efficient doxorubicin nanocarriers, with the emphasis on the main achievements of 2010–2020. Numerous publications have been reviewed to provide an essential summation of the nanopolymer types and their essential properties, mechanisms towards efficient drug delivery, as well as active targeting stimuli-responsive strategies that are currently utilized in the doxorubicin transportation field.

show abstract

“…They became increasingly complex, and it became possible to control their chemical and physical properties. Since many aspects of these topics were thoroughly described in previous reviews, we focused on the latest trends in the doxorubicin delivery systems combined with increasingly innovative systems [44,45]. Additionally, we summarized the progress achieved within the last few years in the field of co-delivery for DOX and siRNA to overcome multidrug resistance.…”

Section: From Macro-to Nanoscalementioning

confidence: 99%

Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies

Butowska

Woziwodzka

Borowik

et al. 2021

Preprint

View full text Add to dashboard Cite

Doxorubicin, a member of the anthracycline family, is a common anticancer agent often used as a first line treatment for the wide spectrum of cancers. Doxorubicin-based chemotherapy, although effective, is associated with serious side effects, such as irreversible cardiotoxicity or nephrotoxicity. Those often life-threatening adverse risks, responsible for the elongation of the patients' recuperation period and increasing medical expenses, have prompted the need for creating novel and safer drug delivery systems. Among many proposed concepts, polymeric nanocarriers are shown to be a promising approach, allowing for controlled and selective drug delivery simultaneously enhancing its activity towards cancerous cells and reducing toxic effects on healthy tissues. This article is a chronological examination of the history of the work progress on polymeric nanostructures, designed as efficient doxorubicin nanocarriers, with the emphasis on the main achievements of 2010-2020. Numerous publications have been reviewed to provide an essential summation of the nanopolymer types and their essential properties, mechanisms towards efficient drug delivery, as well as active targeting stimuli-responsive strategies that are currently utilized in the doxorubicin transportation field.

show abstract

Molecular platforms for targeted drug delivery

Cited by 26 publications

References 229 publications

Trends in Therapeutic Conjugates: Bench to Clinic

Trends in Therapeutic Conjugates: Bench to Clinic

Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies

Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies

Contact Info

Product

Resources

About